PACS Group reports Q1 results on May 20 carrying a sharply different positioning picture than it had just six weeks ago. Short interest has climbed 30% over the past month to 3% of the free float, while the stock itself has rallied 13% over the same period — a divergence that frames the debate heading into tomorrow's print.
The most notable shift is in short positioning. Bears have been adding steadily since mid-April, with short shares jumping roughly 12% in the past week alone from 4.25 million to 4.76 million. Despite that build, the borrow market tells a relaxed story: cost to borrow is just 0.46% and availability is generous at 739%, meaning there is no squeeze pressure in the lending pool. Shorts are building, but they are not fighting over scarce supply to do it. Options positioning has turned modestly more defensive than usual into the print, with the put/call ratio at 0.17 — running about 1.8 standard deviations above its 20-day average of 0.13. That is still a low absolute reading, but the relative spike over the past week signals that some participants are paying for downside protection ahead of the release.
The analyst community, by contrast, has moved firmly in the other direction. Truist Securities raised its target to $52 this morning, maintaining Buy, while Oppenheimer lifted to $48 last week, up from $42. The consensus mean target sits at $49.17 against a last close of $37.48 — implying roughly 31% upside. The direction of travel is clear: analysts have been ratcheting targets higher through 2026 as PACS's earnings momentum has impressed. The company ranks in the 90th percentile on 30-day EPS momentum and the 79th on EPS surprise, reflecting a track record of beating estimates that the Street appears to be rewarding. At a P/E of around 15x and EV/EBITDA of 14.7x, valuation is not stretched for a post-acute care operator delivering this kind of earnings growth.
The insider picture adds one cautionary note. The President/COO sold $6.5 million of stock on April 15 — the largest single insider transaction in the past 90 days — alongside smaller sales from the Chief Legal Officer and Chief Accounting Officer on the same date. Net insider activity over 90 days totals roughly $13.5 million in sales. These reads as routine scheduled disposals rather than conviction calls, but the one-sided flow is worth noting alongside the short build.
The earnings release will test whether the company's accelerating revenue and margin profile — consensus pegs full-year revenue near $5.7 billion with net income around $355 million — can justify the 13% monthly price run and reset analyst targets higher still, or whether the rising short interest reflects legitimate concern that the rally has gotten ahead of near-term fundamentals.
See the live data behind this article on ORTEX.
Open PACS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
